四关节盒激酶1是结肠癌的重要分子标志物

Objective This study aimed to evaluate the expression pattern and prognostic value of the four-jointed box kinase 1(FJX1) gene in colon cancer. Methods Based on the analysis of the public database, the expression, survival differences, enrichment, immunological properties and drug sensitivity of FJX1 were investigated. The expression level of FJX1 was verified by immunohistochemistry. Results The results of bioinformatics analysis indicated that FJX1 was significantly upregulated in colon cancer. Patients with high expression had a poorer overall survival rate, and the differentially expressed genes were enriched in pathways such as the formation of neutrophil extracellular traps. The immune infiltration level and tumor immune dysfunction in the high-expression group were associated with a higher rejection score(TIDE score). Various drugs such as Vemurafenib were negatively correlated with FJX1 expression. Immunohistochemical verification of clinical samples showed that FJX1 was highly expressed in colon cancer tissues. Conclusion FJX1 is upregulated in colon cancer and is associated with an unfavorable prognosis. It may serve as a potential molecular biomarker and provide a basis for future mechanistic and therapeutic studies.